Leriglitazone has met the primary endpoint in NEXUS, the pivotal trial for pediatric pati... 11/12/2024 Healthcare Rare diseases Statistically significant difference in arrested disease in leriglitazone treated patients when compared to the natural... Partners - Minoryx Therapeutics
Biotechnology revolutionizes the diagnosis and treatment of lymphoma, the seventh most com... 15/09/2024 Healthcare Rare diseases Personalized medicine Advanced therapies It is estimated that in 2024, around 12,400 new cases of lymphoma will be diagnosed in Spain, the majority... AseBio
Biotechnology revolutionizes the diagnosis and treatment of lymphoma, the seventh most com... 15/09/2024 There are more than 40 types of lymphomas that can generally be grouped into two major subgroups: Hodgkin lymphoma and... AseBio
ORYZON continues to strengthen its patent portfolio for vafidemstat with additional “Decis... 03/09/2024 Healthcare Rare diseases Innovative drugs In Australia, Malaysia and Mexico. Partners - Oryzon Genomics
How to Leverage Real-World Evidence for Market Access in Rare Disease 16/08/2024 Healthcare Rare diseases A good way to identify the right data source for a targeted rare disease is to perform a real-world data (RWD) source... Partners - Alira Health
Integra Therapeutics to receive up to €10.5 million from European Commission for its FiCAT... 17/07/2024 Healthcare Access to innovation Rare diseases Advanced therapies EU projects This funding will enable Integra Therapeutics to launch its first gene therapy to treat a serious pediatric hepatic... Partners - Integra Therapeutics S.L.
Almirall and the Centre for Genomic Regulation (CRG) Advance Research on Atopic Dermatitis 02/07/2024 Healthcare Access to innovation Rare diseases The research objectives of this collaboration include the characterization of experimental models of AD to identity... Partners - Almirall
BCN HEALTH publishes a study evaluating the use of resources and medical costs of septic a... 01/07/2024 Healthcare Rare diseases The objective of this study was to review the characteristics of patients admitted with septic arthritis in Spanish... Partners - BCN Health
Oryzon announces presentation of final data from PORTICO, vafidemstat’s global Phase IIb ... 26/06/2024 Healthcare Access to innovation Rare diseases Advanced therapies Seleccionada para presentación oral. La conferencia se celebrará en Milán del 21-23 de septiembre. Partners - Oryzon Genomics
ORYZON presents preliminary data from ongoing Phase Ib FRIDA trial with iadademstat plus ... 14/06/2024 Healthcare Access to innovation Drug discovery Rare diseases Data from the first two cohorts demonstrated that combination of iadademstat plus gilteritinib was safe and showed... Partners - Oryzon Genomics
